Eisai Presents Latest Alzheimer's Disease Pipeline and Research Findings at AAIC 2025

Eisai will present data on lecanemab, a treatment for Alzheimer's disease, at the Alzheimer's Association International Conference 2025. Key presentations include four-year efficacy and safety data, subcutaneous maintenance dosing, and real-world case studies. Eisai will also present data on a new immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid and its anti-MTBR tau antibody, etalanetug.

Eisai Inc. is set to present significant findings from its Alzheimer's disease (AD) pipeline at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto and virtually from July 27 to 31. The company will focus on lecanemab, an anti-amyloid beta (Aβ) protofibril antibody, and etalanetug, an anti-MTBR tau antibody.

Key presentations include:

1. Four-Year Data on Lecanemab: On Wednesday, July 30, Eisai will present initial four-year findings from the Phase 3 Clarity AD Open-Label Extension in Early Alzheimer's Disease trial. This data will provide insights into lecanemab's long-term efficacy and safety [1].

2. Subcutaneous Maintenance Dosing: Also on Wednesday, July 30, a session will discuss the potential of a new subcutaneous formulation for lecanemab, offering patients a more convenient option for ongoing treatment [1].

3. Real-World Case Studies: On Sunday, July 27, Eisai will share real-world case studies and patient pathway learnings from diverse U.S. clinical settings two years post-approval of lecanemab [1].

4. Cerebrospinal Fluid (CSF) Analysis: A poster presentation on Monday, July 28, will showcase findings from CSF samples collected from the Clarity AD trial, analyzed using a novel, sensitive immunoassay to measure Aβ protofibrils [1].

5. Etanetug with Lecanemab: On Wednesday, July 30, Eisai will present findings from the Anti-Tau Etalanetug (E2814) with Lecanemab Therapy in Individuals with Dominantly Inherited Alzheimer's Disease: A First Look at Baseline Characteristics and Impact of 6-Month Lecanemab Treatment on Amyloid PET and Safety in the DIAN-TU-001 NexGen Trial [1].

These presentations underscore Eisai's commitment to advancing the diagnosis and treatment of AD, a progressive, neurotoxic disease. The company remains hopeful about the future of dual-acting therapies and real-world data that can improve patient outcomes.

References

[1] https://www.prnewswire.com/news-releases/eisai-to-present-four-year-efficacy-and-safety-data-on-continuous-treatment-with-lecanemab-at-the-alzheimers-association-international-conference-2025-302509714.html